Amgen just got one step closer to bringing its Ozempic competitor to market
Amgen (AMGN) is getting closer to challenging the weight-loss drug duopoly of Novo Nordisk (NVO), the maker of Ozempic and Wegovy, and Eli Lilly (LLY), which produces Zepbound.
This Could Be the Best GLP-1 Stock to Buy in 2025
That's a potential steal. The average stock in the Health Care Select Sector SPDR Fund trades at a multiple of just under 18 ...
Reuters1mon
Amgen profits rise, next MariTide studies start by mid-year
MariTide Phase 3 studies to begin in first half of year FDA places hold on AMG 513 obesity drug trial Amgen's Q4 earnings beat estimates, revenue up 11% Feb 4 (Reuters) - Amgen (AMGN.O), opens new ...
Seeking Alpha28d
Amgen Q4 Earnings: Good Quarter, Ok Guidance, But MariTide Concerns Me (Rating Downgrade)
MariTide's development in obesity treatment is crucial, but concerns about its progress and competition from Novo and Lilly remain. Despite strong performance, Amgen's high debt levels and ...
FierceBiotech29d
Amgen's early-stage obesity asset slapped with FDA hold
Amgen’s mysterious obesity asset will remain a mystery for a bit longer—the FDA has put the candidate’s phase 1 trial on a clinical hold, the company announced Feb. 4. Amgen has not detailed ...